Physician profile
Gerti Tashko
NPI 1669688024
$106,317.60
in general payments reported to CMS, 2019-2025
23 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $11K · 2021: $10K · 2022: $21K · 2023: $11K · 2024: $2,537 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $2,438 · Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,011.00 |
| Travel and Lodging | $2,438.00 |
| Food and Beverage | $179.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $96,082.07 | 2019-2024 | Rybelsus, Ozempic, Saxenda |
| Corcept Therapeutics | $9,433.04 | 2019-2021 | |
| Dexcom, INC. | $114.82 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Abbott Laboratories | $106.44 | 2020-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $93.78 | 2020-2022 | |
| Lilly USA, LLC | $66.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $49.90 | 2019 | |
| Amneal Pharmaceuticals LLC | $46.03 | 2021-2022 | |
| Insulet Corporation | $45.35 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $36.57 | 2022-2023 | Recorlev |
| Abbvie INC. | $35.98 | 2021 | |
| Ibsa Pharma INC. | $32.02 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.00 | 2021 | |
| Radius Health, INC. | $25.31 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.83 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $16.68 | 2019 | |
| Mannkind Corporation | $16.53 | 2022 | |
| Acerus Pharmaceuticals Corporation | $15.15 | 2021 | |
| Amgen INC. | $13.80 | 2020 | |
| Medtronic Minimed, INC. | $13.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.06 | 2020 | |
| Clarus Therapeutics INC. | $12.24 | 2021 | |
| Travere Therapeutics, INC. | $1.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerti Tashko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.